This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds. 

The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach. 

An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the US is focused on incubating and investing in longevity-focused companies that aim to improve quality of life for older adults. The firm primarily invests at the Seed and Series A stages, with typical initial check sizes ranging from $100,000 to $500,000. The investment focus is on opportunities based in the United States. 

The firm invests broadly across the life sciences and healthcare sectors, provided there is a clear connection to aging and longevity. Areas of interest include healthcare quality and cost, care capacity, healthcare benefits activation, aging in place, and financial longevity. The firm has made investments in medical devices, diagnostics, and digital health companies, and currently maintains an active portfolio of more than 15 companies. It generally does not invest in biotech. The firm is open to backing companies at the earliest stages of development. 

There are no specific requirements regarding company structure or founding team experience. The firm is flexible in its role and may choose to lead or co-invest depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This venture capital firm with offices in the US is exclusively focused on the AI transformation of healthcare, operating through a physician-centric model that leverages a broad network of medical professionals actively involved in both the investment process and the development of AI solutions, particularly in medical imaging. 

The firm invests at the pre-Seed, Seed, and Series A stages, with typical check sizes ranging from $1 million to $2 million. While most investments have been made in U.S.-based companies, the firm remains open to international opportunities, including those in Europe and Asia. 

Investment focus is tightly concentrated on disruptive AI-driven technologies in the medical imaging market. The firm does not invest in traditional therapeutics or medical devices, and is currently not considering opportunities outside of AI-centric digital health technologies related to imaging. It is open to investing in companies as early as the pre-prototype stage, provided they are aligned with the firm’s strategic thesis. 

The firm seeks to partner with highly driven management teams who possess deep domain expertise across imaging, artificial intelligence, and medical software. While the firm typically co-invests, it maintains an active, hands-on approach, especially through the support of its physician investor network, which helps accelerate product development and clinical relevance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This life sciences-focused investment firm backed by a prominent family office is actively investing in life science and healthcare companies across the globe, with a focus on those that are based near their headquarters. 

The firm invests in early-stage healthcare companies, with interest in therapeutics, diagnostics, and digital health. It is agnostic to technology type and therapeutic indication, but prefers opportunities with robust pre-clinical data. The firm is open to both pre-clinical and clinical-stage projects, though it does not invest in medical device companies at this time. 

The firm is focused on supporting innovative technologies and is open to partnering with both first-time and experienced founding teams. It is flexible in its role, willing to act as either a lead investor or a co-investor, depending on the structure and needs of the financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This corporate strategic evergreen fund based in the US has invested in over 50 life sciences companies and considers both public and private opportunities in the United States and internationally. The firm is a flexible investor, with initial allocations typically ranging from $1 million to $10 million, depending on the developmental stage of the company. 

The firm invests in therapeutics and medical devices, with the latter limited to implantable products requiring PMA submission. It invests exclusively in companies with clinical-stage assets, and is indication-agnostic, open to innovation across all areas of medicine. 

This investor adopts a flexible approach to management teams, and is willing to take a more hands-on role in cases where founding teams have limited internal resources. A high level of transparency is required from portfolio companies, and the firm actively supports strategic planning around value-driving clinical studies that can meaningfully advance the company’s trajectory. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Europe-based venture capital firm invests across two primary verticals: healthcare innovation and sustainability. The firm typically invests at the seed stage, with initial check sizes ranging from €1 million to €5 million. Its geographic deployment is relatively balanced, with approximately half of investments made in Europe and the other half in the United States. The firm shows particular interest in U.S.-based companies founded by European entrepreneurs. 

The firm invests across therapeutics, diagnostics, medical devices, and digital health, taking an agnostic approach within these sectors. It does not enforce strict criteria regarding the composition or background of founding teams. 

Open to both leading and co-investing, the firm places strong emphasis on the mission and purpose behind each company, placing value on teams with a compelling “why” that drives their approach to solving pressing problems in healthcare. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.